Methods for improving islet signaling in diabetes mellitus and for its prevention

US6890905B2 · kind B2 · utility

Assignee

• Prosidion Limited · GB

Inventors

• Hans-Ulrich Demuth · Halle (Saale), DE
• Konrad Glund · Halle (Saale), DE
• Andrew Pospisilik · West Vancouver, CA
• Kerstin Kuehn-Wache · Halle (Saale), DE

Key dates

• Filing date: Aug 9, 2002
• Grant date: May 10, 2005
• Expiry date: Sep 30, 2022

Classification

• Technology area (CPC A): Human Necessities
• CPC primary: A61K31/426
• WIPO field: Pharmaceuticals
• WIPO sector: Chemistry

Abstract

The present invention discloses methods for therapeutically treating mammals, including but not limited to humans, to increase the relative insulin producing performance of endogenous pancreatic β-cells, to cause differentiation of pancreatic epithelial cells into insulin producing β-cells, to improve muscle sensitivity to insulin and other weight control efforts by the chronic oral administration of a DP IV-inhibitor. The administration causes the active form of GLP-1 and other non-nutrient stimulated growth hormones to remain biologically active longer under physiological conditions. The extended presence of such hormones, in particular in the pancreatic tissue can also facilitate differentiation and regeneration of the β-cells already present that are in need of repair.